{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Zhu J"],"funding":["National Cancer Institute","NCI NIH HHS"],"pagination":["4901-4911"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8496948"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["20(10)"],"pubmed_abstract":["Serum-derived extracellular vesicles (EVs) are a promising source of biomarkers; however, major challenges in EV separation and proteomic profiling remain for isolating EVs from a small amount, that is, on the microliter scale, of human serum while minimizing the contamination of blood proteins and lipoprotein particles coeluting in EV preparations. Herein we have developed a column-based CD9-antibody-immobilized high-performance liquid chromatography immunoaffinity chromatography(CD9-HPLC-IAC) technology for EV isolation from a microliter scale of serum for downstream proteomic analysis. The CD9-HPLC-IAC method achieved EV isolation from 40 μL of serum in 30 min with a yield of 8.0 × 10<sup>9</sup> EVs, where EVs were further processed with a postcolumn cleaning step using the 50 kDa mole"],"journal":["Journal of proteome research"],"pubmed_title":["Column-based Technology for CD9-HPLC Immunoaffinity Isolation of Serum Extracellular Vesicles."],"pmcid":["PMC8496948"],"funding_grant_id":["R50 CA221808","R21CA189775","R01 CA160254","R21 CA189775"],"pubmed_authors":["Zhu J","Ji X","Zhang J","Tan Z","Lubman DM"],"additional_accession":[]},"is_claimable":false,"name":"Column-based Technology for CD9-HPLC Immunoaffinity Isolation of Serum Extracellular Vesicles.","description":"Serum-derived extracellular vesicles (EVs) are a promising source of biomarkers; however, major challenges in EV separation and proteomic profiling remain for isolating EVs from a small amount, that is, on the microliter scale, of human serum while minimizing the contamination of blood proteins and lipoprotein particles coeluting in EV preparations. Herein we have developed a column-based CD9-antibody-immobilized high-performance liquid chromatography immunoaffinity chromatography(CD9-HPLC-IAC) technology for EV isolation from a microliter scale of serum for downstream proteomic analysis. The CD9-HPLC-IAC method achieved EV isolation from 40 μL of serum in 30 min with a yield of 8.0 × 10<sup>9</sup> EVs, where EVs were further processed with a postcolumn cleaning step using the 50 kDa mole","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Oct","modification":"2026-06-01T02:23:02.104Z","creation":"2025-04-04T10:27:46.342Z"},"accession":"S-EPMC8496948","cross_references":{"pubmed":["34473505"],"doi":["10.1021/acs.jproteome.1c00549"]}}